STOCK TITAN

Point72 / Steven A. Cohen Discloses 3.9% Holding in BCYC ADSs

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Point72 entities and Steven A. Cohen report beneficial ownership of 1,860,317 ADSs of Bicycle Therapeutics plc, equal to 3.9% of the outstanding ordinary share class. The ADSs are quoted on Nasdaq under ticker BCYC and each ADS represents one ordinary share. The holdings are reported as shared voting and dispositive power, with no sole voting or dispositive power disclosed.

The filing clarifies that Point72 Asset Management acts as investment manager for the fund holding these ADSs, Point72 Capital Advisors is the general partner, and Mr. Cohen controls the reporting entities. The statement notes the position was not acquired to change or influence control of the issuer.

Positive

  • Clear disclosure of beneficial ownership level: 1,860,317 ADSs representing 3.9% of the class.
  • Proper identification of reporting chain and control relationships (Point72 Asset Management, Point72 Capital Advisors, Steven A. Cohen).

Negative

  • None.

Insights

TL;DR: Point72 reports a non-controlling 3.9% stake (1,860,317 ADSs) in BCYC held via managed funds; disclosure signals passive investor interest.

This Schedule 13G/A shows a sub-5% beneficial position reported under passive investor rules rather than an activist 13D. The ownership is material enough to be disclosed but below thresholds that typically trigger control concerns or proxy influence. Shared voting and dispositive power indicates the position is held through managed vehicles with collective decision-making. For market impact, a 3.9% stake by a well-known asset manager can attract attention but does not alone imply governance change or strategic direction.

TL;DR: This filing documents ownership structure and control relationships without asserting intent to influence issuer control.

The filing appropriately identifies the reporting chain: Point72 Asset Management as manager, Point72 Capital Advisors as general partner, and Steven A. Cohen as control person. Filing under Schedule 13G/A and the certification language indicate a passive reporting posture. Shared voting power suggests pooled fund management rather than individual discretionary control. No governance actions, nominations, or group arrangements are disclosed.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Represented by 1,860,317 ADSs (as defined in Item 2(a)).


SCHEDULE 13G




Comment for Type of Reporting Person: Represented by 1,860,317 ADSs.


SCHEDULE 13G




Comment for Type of Reporting Person: Represented by 1,860,317 ADSs.


SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025

FAQ

How many Bicycle Therapeutics (BCYC) shares does Point72 report owning?

Point72 reports beneficial ownership of 1,860,317 ADSs, representing 3.9% of the ordinary share class.

Under which SEC schedule was the BCYC position reported?

The position was reported on Schedule 13G/A, indicating a passive investor filing rather than an activist 13D.

Who are the reporting entities for the BCYC filing?

The filing is by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen.

Does the filing state Point72 seeks to change control of Bicycle Therapeutics?

No. The certification states the securities were not acquired to change or influence control of the issuer.

What type of voting and dispositive power is reported for the BCYC ADSs?

The reporting entities disclose 0 sole voting/dispositive power and 1,860,317 shared voting and dispositive power.
Bicycle Therapeutics Limited

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Latest SEC Filings

BCYC Stock Data

484.88M
49.14M
1.4%
88.35%
2.29%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
CAMBRIDGE